{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:30:22Z","timestamp":1788777022675,"version":"build-2803163510"},"reference-count":70,"publisher":"The Company of Biologists","issue":"7","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Council","award":["MR\/R015767\/1"],"award-info":[{"award-number":["MR\/R015767\/1"]}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Research Council","award":["MR\/T016515\/1"],"award-info":[{"award-number":["MR\/T016515\/1"]}]},{"DOI":"10.13039\/501100000770","name":"The University of Manchester","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Hyperinflammatory disease is associated with an aberrant immune response resulting in cytokine storm. One such instance of hyperinflammatory disease is known as macrophage activation syndrome (MAS). The pathology of MAS can be characterised by significantly elevated serum levels of interleukin-18 (IL-18) and interferon gamma (IFN\u03b3). Given the role for IL-18 in MAS, we sought to establish the role of inflammasomes in the disease process. Using a murine model of CpG-oligonucleotide-induced MAS, we discovered that the expression of the NLRP3 inflammasome was increased and correlated with IL-18 production. Inhibition of the NLRP3 inflammasome or the downstream caspase-1 prevented MAS-mediated upregulation of IL-18 in the plasma but, interestingly, did not alleviate key features of hyperinflammatory disease including hyperferritinaemia and splenomegaly. Furthermore blockade of IL-1 receptor with its antagonist IL-1Ra did not prevent the development of CpG-induced MAS, despite being clinically effective in the treatment of MAS. These data demonstrate that, during the development of MAS, the NLRP3 inflammasome was essential for the elevation in plasma IL-18 \u2013 a key cytokine in clinical cases of MAS \u2013 but was not a driving factor in the pathogenesis of CpG-induced MAS.<\/jats:p>","DOI":"10.1242\/dmm.050762","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T08:37:47Z","timestamp":1716367067000},"source":"Crossref","is-referenced-by-count":16,"title":["The NLRP3 inflammasome is essential for IL-18 production in a murine model of macrophage activation syndrome"],"prefix":"10.1242","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-1134","authenticated-orcid":false,"given":"Tara A.","family":"Gleeson","sequence":"first","affiliation":[{"name":"School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester 1 Division of Neuroscience , , Manchester M13 9PT , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester 2 , Manchester M6 8HD , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester 3 , Manchester M13 9PL , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-6769","authenticated-orcid":false,"given":"Christina","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum 4 (Sobi) , Stockholm 112 76 , Sweden"},{"name":", AB 4 (Sobi) , Stockholm 112 76 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-2968","authenticated-orcid":false,"given":"Catherine B.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester 1 Division of Neuroscience , , Manchester M13 9PT , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester 2 , Manchester M6 8HD , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester 3 , Manchester M13 9PL , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-2381","authenticated-orcid":false,"given":"David","family":"Brough","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester 1 Division of Neuroscience , , Manchester M13 9PT , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester 2 , Manchester M6 8HD , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester 3 , Manchester M13 9PL , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9646-4456","authenticated-orcid":false,"given":"Stuart M.","family":"Allan","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester 1 Division of Neuroscience , , Manchester M13 9PT , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester 2 , Manchester M6 8HD , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester 3 , Manchester M13 9PL , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-3422","authenticated-orcid":false,"given":"Jack P.","family":"Green","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester 1 Division of Neuroscience , , Manchester M13 9PT , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester 2 , Manchester M6 8HD , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester 3 , Manchester M13 9PL , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"2024073008185679100_DMM050762C1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12185-009-0261-1","article-title":"Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study","volume":"89","author":"Abdelkefi","year":"2009","journal-title":"Int. J. Hematol."},{"key":"2024073008185679100_DMM050762C2","doi-asserted-by":"publisher","first-page":"1759720X20974858","DOI":"10.1177\/1759720X20974858","article-title":"Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance","volume":"12","author":"Ajeganova","year":"2020","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"2024073008185679100_DMM050762C3","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00296-016-3545-9","article-title":"Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus","volume":"36","author":"Aytac","year":"2016","journal-title":"Rheumatol. Int."},{"key":"2024073008185679100_DMM050762C4","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3389\/fimmu.2018.02162","article-title":"Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome","volume":"9","author":"Barsalou","year":"2018","journal-title":"Front. Immunol."},{"key":"2024073008185679100_DMM050762C5","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J. Clin. Invest."},{"key":"2024073008185679100_DMM050762C6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"2024073008185679100_DMM050762C7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/RHU.0b013e318205092d","article-title":"Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids","volume":"17","author":"Bruck","year":"2011","journal-title":"J. Clin. Rheumatol."},{"key":"2024073008185679100_DMM050762C8","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/art.37958","article-title":"Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice","volume":"65","author":"Canna","year":"2013","journal-title":"Arthritis. Rheum."},{"key":"2024073008185679100_DMM050762C9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat. Genet."},{"key":"2024073008185679100_DMM050762C10","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"2024073008185679100_DMM050762C11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology (Oxf.)"},{"key":"2024073008185679100_DMM050762C12","doi-asserted-by":"publisher","first-page":"108328","DOI":"10.1016\/j.clim.2019.108328","article-title":"A novel de novo NLRC4 mutation reinforces the likely pathogenicity of specific LRR domain mutation","volume":"211","author":"Chear","year":"2020","journal-title":"Clin. Immunol."},{"key":"2024073008185679100_DMM050762C13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"2024073008185679100_DMM050762C14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"key":"2024073008185679100_DMM050762C15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"2024073008185679100_DMM050762C16","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"2024073008185679100_DMM050762C17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"key":"2024073008185679100_DMM050762C18","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2024073008185679100_DMM050762C19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.hoc.2015.06.007","article-title":"Pathogenesis of hemophagocytic lymphohistiocytosis","volume":"29","author":"Filipovich","year":"2015","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2024073008185679100_DMM050762C20","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"2024073008185679100_DMM050762C21","doi-asserted-by":"publisher","first-page":"e147593","DOI":"10.1172\/jci.insight.147593","article-title":"IFN-gamma is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome","volume":"6","author":"Gao","year":"2021","journal-title":"JCI Insight"},{"key":"2024073008185679100_DMM050762C22","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","article-title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","volume":"131","author":"Girard-Guyonvarc'h","year":"2018","journal-title":"Blood"},{"key":"2024073008185679100_DMM050762C23","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset Still's disease","volume":"55","author":"Girard","year":"2016","journal-title":"Rheumatology (Oxf.)"},{"key":"2024073008185679100_DMM050762C24","doi-asserted-by":"publisher","first-page":"kyac005","DOI":"10.1093\/discim\/kyac005","article-title":"Looking into the IL-1 of the storm: are inflammasomes the link between immunothrombosis and hyperinflammation in cytokine storm syndromes?","volume":"1","author":"Gleeson","year":"2022","journal-title":"Discov. Immunol."},{"key":"2024073008185679100_DMM050762C25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1126\/science.275.5297.206","article-title":"Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme","volume":"275","author":"Gu","year":"1997","journal-title":"Science"},{"key":"2024073008185679100_DMM050762C26","doi-asserted-by":"publisher","first-page":"919973","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front. Immunol."},{"key":"2024073008185679100_DMM050762C27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2177\/jsci.30.428","article-title":"Macrophage activation syndrome associated with adult-onset Still's disease","volume":"30","author":"Iwamoto","year":"2007","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"2024073008185679100_DMM050762C28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s10067-006-0474-0","article-title":"Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis","volume":"26","author":"Jelusic","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"2024073008185679100_DMM050762C29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"2024073008185679100_DMM050762C30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3899\/jrheum.121098","article-title":"Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome","volume":"40","author":"Kahn","year":"2013","journal-title":"J. Rheumatol."},{"key":"2024073008185679100_DMM050762C31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3&lt;550::AID-ANR103&gt;3.0.CO;2-5","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease","volume":"44","author":"Kawashima","year":"2001","journal-title":"Arthritis. Rheum."},{"key":"2024073008185679100_DMM050762C32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-021-03218-7","article-title":"NINJ1 mediates plasma membrane rupture during lytic cell death","volume":"591","author":"Kayagaki","year":"2021","journal-title":"Nature"},{"key":"2024073008185679100_DMM050762C33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1039\/C3MT00347G","article-title":"Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells","volume":"6","author":"Kell","year":"2014","journal-title":"Metallomics"},{"key":"2024073008185679100_DMM050762C34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cei.13543","article-title":"The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis\/macrophage activation syndrome - a systematic review","volume":"203","author":"Krei","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"2024073008185679100_DMM050762C35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.7150\/ijbs.25743","article-title":"IL-15 generates IFN-\u03b3-producing cells reciprocally expressing lymphoid-myeloid markers during dendritic cell differentiation","volume":"15","author":"Kwon","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"2024073008185679100_DMM050762C36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2024073008185679100_DMM050762C37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","article-title":"Macrophage activation syndrome complicating adult onset Still's disease: a single center case series and comparison with literature","volume":"45","author":"Lenert","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"2024073008185679100_DMM050762C38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10067-017-3625-6","article-title":"Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China","volume":"37","author":"Liu","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"2024073008185679100_DMM050762C39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"key":"2024073008185679100_DMM050762C40","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","article-title":"Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome","volume":"106","author":"Mazodier","year":"2005","journal-title":"Blood"},{"key":"2024073008185679100_DMM050762C41","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1111\/bph.12955","article-title":"Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP","volume":"172","author":"Mcgrath","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"2024073008185679100_DMM050762C42","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"2024073008185679100_DMM050762C43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"2024073008185679100_DMM050762C44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxf.)"},{"key":"2024073008185679100_DMM050762C45","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/iai.57.2.590-595.1989","article-title":"Endotoxin-induced serum factor that stimulates gamma interferon production","volume":"57","author":"Nakamura","year":"1989","journal-title":"Infect. Immun."},{"key":"2024073008185679100_DMM050762C46","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s12185-022-03430-9","article-title":"Anakinra for the treatment of adult secondary HLH: a retrospective experience","volume":"116","author":"Naymagon","year":"2022","journal-title":"Int. J. Hematol."},{"key":"2024073008185679100_DMM050762C47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1074-7613(00)80013-8","article-title":"Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response","volume":"10","author":"Novick","year":"1999","journal-title":"Immunity"},{"key":"2024073008185679100_DMM050762C48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-\u03b3 production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"2024073008185679100_DMM050762C49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","article-title":"Intravenous administration of anakinra in children with macrophage activation syndrome","volume":"19","author":"Phadke","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"2024073008185679100_DMM050762C50","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"key":"2024073008185679100_DMM050762C51","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"2024073008185679100_DMM050762C52","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-t cell therapy in adults; a review of the literature and a survey of practice within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front. Immunol."},{"key":"2024073008185679100_DMM050762C53","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"2024073008185679100_DMM050762C54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","article-title":"The genetics of macrophage activation syndrome","volume":"21","author":"Schulert","year":"2020","journal-title":"Genes Immun."},{"key":"2024073008185679100_DMM050762C55","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.4049\/jimmunol.139.5.1546","article-title":"A urine inhibitor of interleukin 1 activity that blocks ligand binding","volume":"139","author":"Seckinger","year":"1987","journal-title":"J. Immunol."},{"key":"2024073008185679100_DMM050762C56","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2012-07-440339","article-title":"Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11","volume":"121","author":"Sepulveda","year":"2013","journal-title":"Blood"},{"key":"2024073008185679100_DMM050762C57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"2024073008185679100_DMM050762C58","doi-asserted-by":"publisher","first-page":"750114","DOI":"10.3389\/fimmu.2021.750114","article-title":"Usefulness of interleukin-18 as a diagnostic biomarker to differentiate adult-onset still's disease with\/without macrophage activation syndrome from other secondary hemophagocytic lymphohistiocytosis in adults","volume":"12","author":"Shiga","year":"2021","journal-title":"Front. Immunol."},{"key":"2024073008185679100_DMM050762C59","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology (Oxf.)"},{"key":"2024073008185679100_DMM050762C60","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine"},{"key":"2024073008185679100_DMM050762C61","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbi.2017.08.005","article-title":"Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma","volume":"66","author":"Sun","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"2024073008185679100_DMM050762C62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-2141.1999.01504.x","article-title":"Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity","volume":"106","author":"Takada","year":"1999","journal-title":"Br. J. Haematol."},{"key":"2024073008185679100_DMM050762C63","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.4049\/jimmunol.159.12.6156","article-title":"Regulation of IL-18 (IFN-gamma-inducing factor) gene expression","volume":"159","author":"Tone","year":"1997","journal-title":"J. Immunol."},{"key":"2024073008185679100_DMM050762C64","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ccell.2020.09.019","article-title":"Cytokine storms in cancer and COVID-19","volume":"38","author":"Turnquist","year":"2020","journal-title":"Cancer Cell"},{"key":"2024073008185679100_DMM050762C65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.it.2011.01.003","article-title":"Inflammasome activation and IL-1beta and IL-18 processing during infection","volume":"32","author":"Van De Veerdonk","year":"2011","journal-title":"Trends Immunol."},{"key":"2024073008185679100_DMM050762C66","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"2024073008185679100_DMM050762C67","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1124\/jpet.106.111344","article-title":"(S)-1-((S)-2-[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18","volume":"321","author":"Wannamaker","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024073008185679100_DMM050762C68","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"2024073008185679100_DMM050762C69","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxf.)"},{"key":"2024073008185679100_DMM050762C70","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","article-title":"IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxf.)"}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.050762\/3466357\/dmm050762.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.050762\/3556572\/dmm050762.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.050762\/3556572\/dmm050762.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:20:03Z","timestamp":1722313203000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/17\/7\/dmm050762\/361333\/The-NLRP3-inflammasome-is-essential-for-IL-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.050762","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.27.582284","asserted-by":"object"}]},"ISSN":["1754-8403","1754-8411"],"issn-type":[{"value":"1754-8403","type":"print"},{"value":"1754-8411","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"dmm050762"}}